Highlights Celularity Inc.

Equities

CELU

US1511902041

Market Closed - Nasdaq Other stock markets 04:00:00 2024-06-10 pm EDT			5-day change	1st Jan Change
3.25 ^USD	0.00%		+3.17%	+31.37%

Jun. 03	Celularity Presents Data of the Effect of Its T-Cell Platform on Multiple Hematological and Solid Tumors At the American Society of Clinical Oncology Annual Meeting	CI
May. 21	Transcript : Celularity Inc. - Analyst/Investor Day

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Celularity Presents Data of the Effect of Its T-Cell Platform on Multiple Hematological and Solid Tumors At the American Society of Clinical Oncology Annual Meeting	Jun. 03	CI
Celularity Receives Healthcare Common Procedure Coding System Q Code Approval from the U.S. Centers for Medicare & Medicaid Services for Biovance 3L	Mar. 26	CI
Celularity to Execute Reverse Stock Split Next Week	Feb. 23	MT
Celularity Inc. Provides Sales Guidance for the First Quarter and Full Year 2024	Feb. 01	CI
Celularity, BioCellgraft Strike Deal for Placental-Derived Biomaterial Products	Jan. 04	MT
Celularity Inc. Confirms Commercialization Agreement with BioCellgraft, Inc. for Manufacture and Distribution of Advanced Biomaterial Products for Use in Oral Healthcare	Jan. 04	CI
Celularity Inc. Provides Earnings Guidance for the Fourth Quarter and Full Year 2023	Jan. 03	CI
Celularity Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Jan. 03	CI
North American Morning Briefing : S&P 500 Futures Dip with Fresh Record in Sight	Dec. 20	DJ
Celularity Receives Non-Compliance Notice From Nasdaq	Nov. 24	MT
Celularity to Support Research of Regeneron's Allogeneic Cell Therapy Candidates for Solid Tumors	23-08-29	MT
Celularity Inc Announces Multi-Year Research Collaboration Services Agreement with Regeneron Pharmaceuticals, Inc	23-08-29	CI
Celularity Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-14	CI
Celularity Inc. and Verséa Ophthalmics Announce Exclusive U.S. Commercialization Agreement to Distribute Biovance and Biovance 3L Ocular for Ophthalmic Applications	23-07-27	CI
Celularity Inc. to Present Data from a New Product Technology in Development for Orthopedic Applications at 7th International Conference on Orthopedics	23-06-29	CI
Celularity Inc. Announces $45 Million Purchase Order	23-05-23	CI
Celularity Says it Received $45 Million Purchase Order From Jamjoom Medical Store	23-05-23	MT
Celularity Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-22	CI
Celularity Inc. Announces Results from Exploratory Analysis of Phase 1 Data Evaluating Alterations in Gene and Protein Signatures Associated with Inflammation and Fistula Formation in Patients with Crohn's Disease	23-05-19	CI
Celularity Inc. Announces Preliminary Results from its Phase 1 Trial of CYNK-001, its Investigational Unmodified Natural Killer Cell Therapy in Development for Treatment of R/R AML and MRD Positive AML	23-04-27	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Celularity Inc.

Equities

CELU

US1511902041

Highlights

Filters